Financial & Business News
LATEST INVESTING HEADLINES
Sun Country Airlines has mechanisms to shield financial results, resulting in a 23% stock gain, outperforming the S&P 500's 16% gain. Despite flat third quarter revenues, the company is shifting capacity from scheduled services to charter and cargo, enhancing future performance. I'm increasing my price target for Sun Country Airlines by 17% to $18.28, citing strong growth prospects and improved EBITDA estimates.
LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024.
LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lilium N.V. ("Lilium" or "the Company") (NASDAQ:LILM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ASPI Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / November 27, 2024 / On Nov. 26, 2024, the price of ASP Isotopes (NASDAQ:ASPI) crashed as much as 30% during intraday trading after Fuzzy Panda Research published a sensational report claiming ASPI uses outdated equipment and is secretly paying for stock promotion. The report has prompted shareholder rights firm Hagens Berman to commence an investigation into the allegations.
Indian stocks and the related ETFs cooled off in September and into October after Prime Minister Narendra Modi's National Democratic Alliance (NDA) didn't have the expected electoral success. This sparked a sell-off in previously hot Indian equities.
While many investors seem fixated on the mega cap equities, one would be remiss to ignore the immense potential of SMID caps. There are more than a few reasons why SMID caps currently offer an attractive investment option.
Thematic ETFs have had a tough slog – now headed for a third-straight year of losses. Roughly 90 thematic ETFs debuted back in 2021, compared to fewer than 20 this year.
VettaFi's Head of Research Todd Rosenbluth discussed the Vanguard S&P 500 ETF (VOO) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and strategy, visit the Fixed Income Channel.
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company's strong cash position and strategic focus on RAS-driven cancers offer significant growth opportunities without imminent dilution risks. Upcoming catalysts include FDA filing decisions, interim data from NSCLC and pancreatic cancer trials, and potential commercial launch, driving Verastem's bullish outlook.